Nanodrugs in liposome‐ or albumin‐based formulations are already used in the clinic for some forms of cancers (Barenholz, 2012; Sethi et al, 2013; Von Hoff et al, 2013), and others are being tested in pre‐clinical trials (Tasciotti et al, 2008; Shen et al, 2013). The gene discussed is ALB; the disease is cancer.